A	a	O	O	O	O
cross-sectional	cross-sectional	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
selective	selective	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
reuptake	reuptake	O	O	OTHERS	I
inhibitors	inhibitors	O	O	OTHERS	I
on	on	O	O	O	O
bone	bone	O	O	O	O
mineral	mineral	O	O	O	O
density	density	O	O	O	O
in	in	O	O	O	O
boys	boys	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
aim	aim	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
investigate	investigate	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
risperidone-induced	risperidone-induced	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
on	on	O	O	O	O
trabecular	trabecular	O	O	O	O
bone	bone	O	O	O	O
mineral	mineral	O	O	O	O
density	density	O	O	O	O
(	(	O	O	O	O
BMD	bmd	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
children	children	O	O	O	O
and	and	O	O	O	O
adolescents	adolescents	O	O	O	O
.	.	O	O	O	O

METHOD	method	O	O	O	O
:	:	O	O	O	O
Medically	medically	O	O	O	O
healthy	healthy	O	O	O	O
7-	7-	O	O	O	O
to	to	O	O	O	O
17-year-old	17-year-old	O	O	O	O
males	males	O	O	O	O
chronically	chronically	O	O	O	O
treated	treated	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
naturalistic	naturalistic	O	O	O	O
setting	setting	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
recruited	recruited	O	O	O	O
for	for	O	O	O	O
this	this	O	O	O	O
cross-sectional	cross-sectional	O	O	O	O
study	study	O	O	O	O
through	through	O	O	O	O
child	child	O	O	O	O
psychiatry	psychiatry	O	O	O	O
outpatient	outpatient	O	O	O	O
clinics	clinics	O	O	O	O
between	between	O	O	O	O
November	november	O	O	O	O
2005	2005	O	O	O	O
and	and	O	O	O	O
June	june	O	O	O	O
2007	2007	O	O	O	O
.	.	O	O	O	O

Anthropometric	anthropometric	O	O	O	O
measurements	measurements	O	O	O	O
and	and	O	O	O	O
laboratory	laboratory	O	O	O	O
testing	testing	O	O	O	O
were	were	O	O	O	O
conducted	conducted	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
clinical	clinical	O	O	O	O
diagnoses	diagnoses	O	O	O	O
were	were	O	O	O	O
based	based	O	O	O	O
on	on	O	O	O	O
chart	chart	O	O	O	O
review	review	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
developmental	developmental	O	O	O	O
and	and	O	O	O	O
treatment	treatment	O	O	O	O
history	history	O	O	O	O
was	was	O	O	O	O
obtained	obtained	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
medical	medical	O	O	O	O
record	record	O	O	O	O
.	.	O	O	O	O

Volumetric	volumetric	O	O	O	O
BMD	bmd	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
ultradistal	ultradistal	O	O	O	O
radius	radius	O	O	O	O
was	was	O	O	O	O
measured	measured	O	O	O	O
using	using	O	O	O	O
peripheral	peripheral	O	O	O	O
quantitative	quantitative	O	O	O	O
computed	computed	O	O	O	O
tomography	tomography	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
areal	areal	O	O	O	O
BMD	bmd	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
lumbar	lumbar	O	O	O	O
spine	spine	O	O	O	O
was	was	O	O	O	O
estimated	estimated	O	O	O	O
using	using	O	O	O	O
dual-energy	dual-energy	O	O	O	O
x-ray	x-ray	O	O	O	O
absorptiometry	absorptiometry	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
present	present	O	O	O	O
in	in	O	O	O	O
49	49	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
83	83	O	O	O	O
boys	boys	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
41	41	O	O	O	O
)	)	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
a	a	O	O	O	O
mean	mean	O	O	O	O
of	of	O	O	O	O
2.9	2.9	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

Serum	serum	O	O	O	O
testosterone	testosterone	CHEMICALS	O	OTHERS	I
concentration	concentration	O	O	O	O
increased	increased	O	O	O	O
with	with	O	O	O	O
pubertal	pubertal	O	O	O	O
status	status	O	O	O	O
but	but	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
affected	affected	O	O	O	O
by	by	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

As	as	O	O	O	O
expected	expected	O	O	O	O
,	,	O	O	O	O
bone	bone	O	O	O	O
mineral	mineral	O	O	O	O
content	content	O	O	O	O
and	and	O	O	O	O
BMD	bmd	O	O	O	O
increased	increased	O	O	O	O
with	with	O	O	O	O
sexual	sexual	O	O	O	O
maturity	maturity	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
adjusting	adjusting	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
stage	stage	O	O	O	O
of	of	O	O	O	O
sexual	sexual	O	O	O	O
development	development	O	O	O	O
and	and	O	O	O	O
height	height	O	O	O	O
and	and	O	O	O	O
BMI	bmi	O	O	O	O
z	z	O	O	O	O
scores	scores	O	O	O	O
,	,	O	O	O	O
serum	serum	O	O	O	O
prolactin	prolactin	O	O	O	O
was	was	O	O	O	O
negatively	negatively	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
trabecular	trabecular	O	O	O	O
volumetric	volumetric	O	O	O	O
BMD	bmd	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
ultradistal	ultradistal	O	O	O	O
radius	radius	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
.03	.03	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Controlling	controlling	O	O	O	O
for	for	O	O	O	O
relevant	relevant	O	O	O	O
covariates	covariates	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
also	also	O	O	O	O
found	found	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
selective	selective	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
reuptake	reuptake	O	O	OTHERS	I
inhibitors	inhibitors	O	O	OTHERS	I
(	(	O	O	O	O
SSRIs	ssris	O	O	OTHERS	I
)	)	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
lower	lower	O	O	O	O
trabecular	trabecular	O	O	O	O
BMD	bmd	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
radius	radius	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
.03	.03	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
BMD	bmd	O	O	O	O
z	z	O	O	O	O
score	score	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
lumbar	lumbar	O	O	O	O
spine	spine	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
.05	.05	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
findings	findings	O	O	O	O
became	became	O	O	O	O
more	more	O	O	O	O
marked	marked	O	O	O	O
when	when	O	O	O	O
the	the	O	O	O	O
analysis	analysis	O	O	O	O
was	was	O	O	O	O
restricted	restricted	O	O	O	O
to	to	O	O	O	O
non-Hispanic	non-hispanic	O	O	O	O
white	white	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
13	13	O	O	O	O
documented	documented	O	O	O	O
fractures	fractures	O	DISEASE	OTHERS	I
,	,	O	O	O	O
3	3	O	O	O	O
occurred	occurred	O	O	O	O
after	after	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
SSRIs	ssris	O	O	OTHERS	I
were	were	O	O	O	O
started	started	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
none	none	O	O	O	O
occurred	occurred	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
This	this	O	O	O	O
is	is	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
study	study	O	O	O	O
to	to	O	O	O	O
link	link	O	O	O	O
risperidone-induced	risperidone-induced	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
SSRI	ssri	O	O	OTHERS	I
treatment	treatment	O	O	O	O
to	to	O	O	O	O
lower	lower	O	O	O	O
BMD	bmd	O	O	O	O
in	in	O	O	O	O
children	children	O	O	O	O
and	and	O	O	O	O
adolescents	adolescents	O	O	O	O
.	.	O	O	O	O

Future	future	O	O	O	O
research	research	O	O	O	O
should	should	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
longitudinal	longitudinal	O	O	O	O
course	course	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
adverse	adverse	O	O	O	O
event	event	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
its	its	O	O	O	O
temporal	temporal	O	O	O	O
stability	stability	O	O	O	O
and	and	O	O	O	O
whether	whether	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
fracture	fracture	O	O	OTHERS	I
rate	rate	O	O	O	O
ensues	ensues	O	O	O	O
.	.	O	O	O	O

